Congress demands Medicare drug cost transparency for seniors
H.R. 6401 — Increasing Medication Access for Seniors Act of 2025 · Filed by Jennifer Kiggans (R-VA) · 1 cosponsor · Introduced Dec 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Secretary of Health and Human Services to report to Congress on how many Medicare Part D beneficiaries are using a monthly capped cost-sharing option for prescription drugs, and what steps HHS is taking to make this option easier to access and understand. The reports must be submitted every 3 months for the first year, then annually through 2031.
Why we flagged it
The bill is a reporting and implementation mandate designed to increase awareness and utilization of an existing Medicare cost-sharing option. It does not create new benefits or change policy; it mandates transparency and operational improvements to help seniors access a benefit that already exists.
What the text implies
- The bill's success depends on HHS actually implementing point-of-sale mechanisms and outreach; if HHS deprioritizes implementation, the reporting requirement alone will not improve access.
- Monthly capped cost-sharing may shift some financial risk from beneficiaries to insurers and the Medicare program, potentially affecting plan design and premiums in future years.
- Increased utilization of this option could reveal gaps in current plan offerings or pricing structures, creating pressure for broader Part D reform.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill creates transparency and accountability around an existing Medicare benefit (monthly capped cost-sharing) that helps seniors manage drug costs predictably. It mandates outreach and point-of-sale implementation to ensure seniors actually know about and can use this option, addressing a real access gap.
Who stands to gain
- Medicare beneficiaries (through improved access to cost-predictability)
- Pharmacy benefit managers and pharmacies (through increased point-of-sale infrastructure investment)
Named in the bill
Department of Health and Human Services, Medicare Part D, Medicare Advantage Plans (MA-PD), Prescription Drug Plans, Medicare.gov, Centers for Medicare & Medicaid Services (implied)
Where it stands
1 cosponsor: 1 Democrats.
- Dec 3, 2025 — Introduced · Congress.gov: “Introduced in House”
- Dec 3, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
2 lobbying clients named this bill on 4 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $220,000 in lobbying spend. A filing names 8 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 41% of bills with at least one filing.
Jennifer Kiggans, the sponsor, reported $1,313,089 in PAC receipts in the 2026 cycle.
- Alliance for Aging Research — $140,000 on 2 filings
- Patient Access Network Foundation — $80,000 on 2 filings
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (3,036 characters) on Aug 21, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress demands Medicare drug cost transparency for seniors” QuorumCivic. https://share.quorumcivic.app/bill/119/hr6401 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.